GeoVax Labs (GOVX) Competitors $0.77 +0.02 (+2.69%) As of 08/22/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GOVX vs. KLRS, ATHE, FGEN, NBRV, PYRGF, TPST, SLGL, GBIO, GRCE, and TELOShould you be buying GeoVax Labs stock or one of its competitors? The main competitors of GeoVax Labs include Kalaris Therapeutics (KLRS), Alterity Therapeutics (ATHE), FibroGen (FGEN), Nabriva Therapeutics (NBRV), PyroGenesis Canada (PYRGF), Tempest Therapeutics (TPST), Sol-Gel Technologies (SLGL), Generation Bio (GBIO), Grace Therapeutics (GRCE), and Telomir Pharmaceuticals (TELO). These companies are all part of the "pharmaceutical products" industry. GeoVax Labs vs. Its Competitors Kalaris Therapeutics Alterity Therapeutics FibroGen Nabriva Therapeutics PyroGenesis Canada Tempest Therapeutics Sol-Gel Technologies Generation Bio Grace Therapeutics Telomir Pharmaceuticals GeoVax Labs (NASDAQ:GOVX) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability. Which has stronger valuation & earnings, GOVX or KLRS? GeoVax Labs has higher revenue and earnings than Kalaris Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeoVax Labs$6.14M2.00-$24.99M-$2.01-0.38Kalaris TherapeuticsN/AN/A-$58.77MN/AN/A Do insiders & institutionals hold more shares of GOVX or KLRS? 6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are held by institutional investors. 1.2% of GeoVax Labs shares are held by company insiders. Comparatively, 75.0% of Kalaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is GOVX or KLRS more profitable? Kalaris Therapeutics has a net margin of 0.00% compared to GeoVax Labs' net margin of -403.88%. Kalaris Therapeutics' return on equity of -81.02% beat GeoVax Labs' return on equity.Company Net Margins Return on Equity Return on Assets GeoVax Labs-403.88% -408.80% -279.89% Kalaris Therapeutics N/A -81.02%-65.15% Does the media prefer GOVX or KLRS? In the previous week, Kalaris Therapeutics had 6 more articles in the media than GeoVax Labs. MarketBeat recorded 8 mentions for Kalaris Therapeutics and 2 mentions for GeoVax Labs. GeoVax Labs' average media sentiment score of 0.59 beat Kalaris Therapeutics' score of -0.16 indicating that GeoVax Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeoVax Labs 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kalaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts prefer GOVX or KLRS? GeoVax Labs currently has a consensus target price of $8.50, suggesting a potential upside of 1,003.90%. Kalaris Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 19.52%. Given GeoVax Labs' stronger consensus rating and higher possible upside, analysts clearly believe GeoVax Labs is more favorable than Kalaris Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeoVax Labs 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Kalaris Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility & risk, GOVX or KLRS? GeoVax Labs has a beta of 3.27, suggesting that its stock price is 227% more volatile than the S&P 500. Comparatively, Kalaris Therapeutics has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. SummaryGeoVax Labs beats Kalaris Therapeutics on 7 of the 13 factors compared between the two stocks. Get GeoVax Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for GOVX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GOVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GOVX vs. The Competition Export to ExcelMetricGeoVax LabsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.94M$3.11B$5.76B$9.61BDividend YieldN/A2.23%4.41%4.10%P/E Ratio-0.3820.8831.1026.04Price / Sales2.00352.10436.34104.14Price / CashN/A43.1937.7358.48Price / Book4.288.129.536.61Net Income-$24.99M-$54.72M$3.26B$265.56M7 Day Performance1.40%2.63%2.10%1.95%1 Month Performance-9.51%2.78%2.81%-0.37%1 Year Performance-87.95%11.01%30.56%19.02% GeoVax Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GOVXGeoVax Labs1.8556 of 5 stars$0.77+2.7%$8.50+1,003.9%-89.5%$11.94M$6.14M-0.3810Short Interest ↑Gap UpKLRSKalaris Therapeutics1.2981 of 5 stars$2.50+1.6%$3.00+20.0%N/A$46.75MN/A0.00110ATHEAlterity Therapeutics2.2064 of 5 stars$5.22-0.6%$12.00+129.9%+280.3%$46.30MN/A0.0010Positive NewsGap UpFGENFibroGen4.6483 of 5 stars$11.30+19.1%$43.00+280.5%+15.8%$45.65M$29.62M-29.74570High Trading VolumeNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070PYRGFPyroGenesis CanadaN/A$0.24-6.1%N/A-63.8%$45.44M$9.14M-4.0490Gap UpHigh Trading VolumeTPSTTempest Therapeutics1.1924 of 5 stars$10.16-3.5%$30.00+195.3%-47.2%$45.11MN/A-0.7020SLGLSol-Gel Technologies1.0195 of 5 stars$16.10+4.3%$40.00+148.4%+226.2%$44.92M$11.54M-13.0950News CoverageEarnings ReportGap DownGBIOGeneration Bio3.1958 of 5 stars$6.63+5.4%$10.67+60.9%-74.4%$44.69M$19.89M-0.61150GRCEGrace Therapeutics3.0101 of 5 stars$3.23-0.9%$12.00+271.5%N/A$44.67MN/A-3.76N/APositive NewsAnalyst UpgradeTELOTelomir Pharmaceuticals2.6939 of 5 stars$1.49flat$15.00+906.7%-74.4%$44.34MN/A-2.761Gap Down Related Companies and Tools Related Companies KLRS Competitors ATHE Competitors FGEN Competitors NBRV Competitors PYRGF Competitors TPST Competitors SLGL Competitors GBIO Competitors GRCE Competitors TELO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GOVX) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeoVax Labs Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeoVax Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access